Since the CD206/CD68 ratio increases in bevacizumab‐treated glioblastomas (“M2‐rich”), one may envision the application of CSF1R inhibitors in GBMs that recur after bevacizumab therapy. The gene discussed is MRC1; the disease is glioblastoma.